Your Article Summary
See Latest ArticlesThe use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
Respiratory Medicine, 06/30/09
Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.
Today in Asthma/Atopy...keeping you current
Receive free subspecialty "5-minute updates" via email
Anti-inflammatory drug therapy in asthma
Paediatric Respiratory Reviews, 11/02/09
Montelukast in the treatment of asthma and beyond
Expert Review of Clinical Immunology, 11/23/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency Department
Archives of Pediatrics and Adolescent Medicine, 11/23/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09